Management of Refractory Dysmenorrhea

First-Line Treatment Options

The Centers for Disease Control and Prevention recommends NSAIDs for 5-7 days during menstruation for dysmenorrhea management 1, 2
Combined oral contraceptives with 30-35 μg ethinyl estradiol are recommended as a first-line treatment option for dysmenorrhea 3

Depot Medroxyprogesterone Acetate (DMPA) can be considered as a second-line treatment option if the first-line options are not effective, with a strength of evidence based on clinical guidelines 3
For breakthrough bleeding with DMPA, NSAIDs for 5-7 days may be effective, as recommended by the Centers for Disease Control and Prevention 4, 5
Amenorrhea is common after ≥1 year of continuous use of DMPA, which may help with dysmenorrhea management, according to the Centers for Disease Control and Prevention 4

For implant users with spotting or light bleeding, the Centers for Disease Control and Prevention recommends NSAIDs for 5-7 days 2, 5
For implant users with heavy or prolonged bleeding, the Centers for Disease Control and Prevention recommends NSAIDs for 5-7 days, hormonal treatment (e.g., low-dose COCs or estrogen) for 10-20 days, or antifibrinolytic agents (e.g., tranexamic acid) for 5 days 2, 5

The Centers for Disease Control and Prevention recommends no routine follow-up visit, but patients should return if experiencing side effects or concerns 1, 6
At follow-up visits, the Centers for Disease Control and Prevention recommends assessing satisfaction with the method, any changes in health status, and monitoring blood pressure for patients on hormonal methods 1, 6